Randomized Trialhigh evidence
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
Lancet (London, England)·June 6, 2026·PMID 42119587
Why it mattersIt provides direct evidence that ongoing pharmacotherapy is critical for weight maintenance, and that dose reduction to 5 mg may be a viable alternative to full discontinuation, informing personalized long-term obesity management.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled